title: [Feasibility of assessing EGFR mutation and others using samples obtained by EBUS transbronchial needle aspiration].
abstract: BACKGROUND
  Assessment of mutation status in patients with non-small cell lung cancer (NSCLC) is often required. The aim of this study was to confirm the feasibility of molecular mutation analysis in cytologic specimens obtained by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).
  
  
  METHODS
  Patients with an EBUS-TBNA positive for adenocarcinoma or NSCLC (squamous cell carcinoma excluded) were included retrospectively from January to December 2010, and prospectively from January to August 2011. Specimens were collected on liquid based preparation and processed on paraffin-embedded cell blocks after ThinPrepÒ procedure. Molecular analysis was performed by a SnaPshot assay for EGFR and by pyrosequencing for KRAS on suitable samples (>5% tumor cells).
  
  
  RESULTS
  Eighty-two patients were included (63 adenocarcinoma). Molecular analysis for EGFR was feasible in 80 (97.6%) patients and for KRAS in 78 (95.1%) patients. Molecular analysis identified EGFR and KRAS mutations in tumor samples from four (5%) and 18 (23%) patients respectively. All EGFR mutations were found in women.
  
  
  CONCLUSIONS
  Molecular analysis mutations can be performed routinely in cytologic specimens obtained by EBUS-TBNA.
authors.affiliation: Service d'endoscopie respiratoire, clinique de pneumologie, hôpital Calmette, pôle cardiovasculaire et pulmonaire, CHRU de Lille, 59000 Lille, France.
authors.forename: S
authors.initials: S
authors.lastname: Boulanger
authors.forename: C
authors.initials: C
authors.lastname: Delattre
authors.forename: C
authors.initials: C
authors.lastname: Descarpentries
authors.forename: F
authors.initials: F
authors.lastname: Escande
authors.forename: B
authors.initials: B
authors.lastname: Bouchindhomme
authors.forename: M-C
authors.initials: MC
authors.lastname: Copin
authors.forename: X
authors.initials: X
authors.lastname: Dhalluin
authors.forename: A
authors.initials: A
authors.lastname: Scherpereel
authors.forename: P-P
authors.initials: PP
authors.lastname: Ramon
authors.forename: A
authors.initials: A
authors.lastname: Cortot
authors.forename: C
authors.initials: C
authors.lastname: Fournier
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000368:Aged; D001999:Bronchoscopy / Q000379:methods*; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000473:pathology*; D004252:DNA Mutational Analysis / Q000379:methods*; D061765:Endoscopic Ultrasound-Guided Fine Needle Aspiration / Q000379:methods*; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D011518:Proto-Oncogene Proteins / Q000235:genetics; D016283:Proto-Oncogene Proteins p21(ras); D012189:Retrospective Studies; D013048:Specimen Handling / Q000379:methods; D018631:ras Proteins / Q000235:genetics
chemical_list: C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins